{
  "symbol": "PHAR",
  "company_name": "Pharming Group N.V. ADR",
  "ir_website": "https://www.pharming.com/investors",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "Pharming Group to participate in November investor conference",
          "url": "https://www.pharming.com/news/pharming-group-to-participate-in-november-investor-conference",
          "content": "![](/assets/images/logo.png)[**Close**](#)\n\nMenu\n\n  * [Home](/)\n  * [Open submenu (About Us)](#mm-2)[About Us](/about-us)\n  * [Products](/products)\n  * [Pipeline](/pipeline)\n  * [Partnering](/partnering)\n  * [Open submenu (Investors)](#mm-5)[Investors](/investors)\n  * [News](/news)\n  * [Careers](/career-opportunities)\n  * [Open submenu (Contact)](#mm-6)[Contact](/contact)\n  * [LanguageVerander taal](/nl/node/495)\n\n\n\n[Close submenu (About Us)](#mm-1)[About Us](#mm-1)\n\n  * [Open submenu (Executive Committee)](#mm-3)[Executive Committee](/about-us/executive-committee)\n  * [Open submenu (Board of Directors)](#mm-4)[Board of Directors](/about-us/board-directors)\n  * [Corporate Governance](/about-us/corporate-governance)\n  * [ESG](/about-us/esg-environmental-social-and-governance \"ESG \\(Environmental, Social and Governance\\)\")\n\n\n\n[Close submenu (Executive Committee)](#mm-2)[Executive Committee](#mm-2)\n\n  * [Sijmen de Vries](/about-us/executive-committee/sijmen-de-vries)\n  * [Jeroen Wakkerman](/about-us/executive-committee/jeroen-wakkerman)\n  * [Anurag Relan](/about-us/executive-committee/anurag-relan)\n  * [Stephen Toor](/about-us/executive-committee/stephen-toor)\n  * [Mireille Sanders, MSc](/about-us/executive-committee/mireille-sanders)\n  * [Ruud van Outersterp](/about-us/executive-committee/ruud-van-outersterp)\n  * [Dr. Alexander Breidenbach](/about-us/executive-committee/alexander-breidenbach)\n\n\n\n[Close submenu (Board of Directors)](#mm-2)[Board of Directors](#mm-2)\n\n  * [Deborah Jorn, MBA](/about-us/board-directors/deborah-jorn)\n  * [Barbara Yanni](/about-us/board-directors/barbara-yanni)\n  * [Mark Pykett, VMD, PhD](/about-us/board-directors/mark-pykett)\n  * [Leonard Kruimer](/about-us/board-directors/leonard-kruimer)\n  * [Jabine van der Meijs](/about-us/board-directors/jabine-van-der-meijs)\n  * [Richard Peters, MD, PhD](/about-us/board-directors/dr-richard-peters)\n  * [Steven Baert](/about-us/board-directors/steven-baert)\n\n\n\n[Close submenu (Investors)](#mm-1)[Investors](#mm-1)\n\n  * [Upcoming events](/investors/upcoming-events)\n  * [Corporate Presentations](/investors/corporate-presentations)\n  * [Shareholder Meetings](/investors/shareholder-meetings)\n  * [Financial documents](/investors/financial-documents)\n  * [Analyst Coverage](/investors/analyst-coverage)\n  * [SEC filings](/investors/sec-filings)\n  * [FAQ](/investors/faq)\n\n\n\n[Close submenu (Contact)](#mm-1)[Contact](#mm-1)\n\n  * [Report an adverse event](/report-adverse-event)\n\n\n\n[ Skip to main content ](#main)\n\nSearch  Search \n\n## [ Pharming  ![Logo Pharming](/assets/images/logo_pharming.svg) ](https://www.pharming.com/) [ Search  ](#searchCollapse) [ Menu  ](#hamburgermenu)\n\nglobal \n\n  * [Home](/)\n  * [About Us](/about-us)\n    * [Executive Committee](/about-us/executive-committee)\n    * [Board of Directors](/about-us/board-directors)\n    * [Corporate Governance](/about-us/corporate-governance)\n    * [ESG](/about-us/esg-environmental-social-and-governance \"ESG \\(Environmental, Social and Governance\\)\")\n  * [Products](/products)\n  * [Pipeline](/pipeline)\n  * [Partnering](/partnering)\n  * [Investors](/investors)\n    * [Upcoming events](/investors/upcoming-events)\n    * [Corporate Presentations](/investors/corporate-presentations)\n    * [Shareholder Meetings](/investors/shareholder-meetings)\n    * [Financial documents](/investors/financial-documents)\n    * [Analyst Coverage](/investors/analyst-coverage)\n    * [SEC filings](/investors/sec-filings)\n    * [FAQ](/investors/faq)\n  * [News](/news)\n  * [Careers](/career-opportunities)\n  * [Contact](/contact)\n    * [Report an adverse event](/report-adverse-event)\n  * [ Search  ](#searchCollapse) [LanguageVerander taal](/nl/node/495)\n\n\n\n  1. [ Home ](/)\n  2. [ News ](/news)\n  3. Pharming Group to participate in November investor conference \n\n\n\n#  Pharming Group to participate in November investor conference \n\nConference attendance  November 5, 2024 \n\n#  Pharming Group to participate in November investor conference \n\nPharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of November: \n\n  * **Jefferies London Healthcare Conference 2024, London, U.K., November 19-21** Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. ([view live webcast](https://wsw.com/webcast/jeff315/phar/1843548))\n\n\n\nFor more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies representative.\n\n[ Download full press release  EN  ](/sites/default/files/imce/Press%20releases/Pharming%20attending%20Investor%20Conferences%20November%202024_EN_05NOV24.pdf)\n\n[ Download volledig persbericht  NL  ](/sites/default/files/imce/Press%20releases/Pharming%20attending%20Investor%20Conferences%20November%202024_NL_05NOV24.pdf)\n\n[ Download presentation slides  EN  ](/sites/default/files/imce/Presentations/Pharming%20Jefferies%20London%20Healthcare%20Conference%20Presentation_20NOV2024.pdf)\n\n[ Download presentation transcript  EN  ](/sites/default/files/imce/Transcripts/Jefferies%20London%20Healthcare%20Conference%20Presentation%20Transcript_20NOV24.pdf)\n\n###  Subscribe to our press release distribution list \n\n####  Stay up to date on the latest news and information \n\nEnglish \n\nDutch \n\nSignup \n\nI understand and consent to the following [ Privacy Statement ](/privacy-statement)\n\nSignup  Signup \n\nCookies:  This website uses cookies [Check the cookies page](/cookies) for more information [ Accept ](javascript\\(\\);) [ Decline ](javascript\\(\\);)\n\n##  Taal aanpassen \n\nWilt u overschakelen naar een andere taal? Klik [ hier ](/nl) voor de Nederlandse website. \n\n[ Taal aanpassen ](/nl) [ Sluiten ](#)\n"
        },
        {
          "title": "Pharming Group reports third quarter 2024 financial results and provides business update",
          "url": "https://www.pharming.com/news/pharming-group-reports-third-quarter-2024-financial-results",
          "content": "![](/assets/images/logo.png)[**Close**](#)\n\nMenu\n\n  * [Home](/)\n  * [Open submenu (About Us)](#mm-2)[About Us](/about-us)\n  * [Products](/products)\n  * [Pipeline](/pipeline)\n  * [Partnering](/partnering)\n  * [Open submenu (Investors)](#mm-5)[Investors](/investors)\n  * [News](/news)\n  * [Careers](/career-opportunities)\n  * [Open submenu (Contact)](#mm-6)[Contact](/contact)\n  * [LanguageVerander taal](/nl/node/494)\n\n\n\n[Close submenu (About Us)](#mm-1)[About Us](#mm-1)\n\n  * [Open submenu (Executive Committee)](#mm-3)[Executive Committee](/about-us/executive-committee)\n  * [Open submenu (Board of Directors)](#mm-4)[Board of Directors](/about-us/board-directors)\n  * [Corporate Governance](/about-us/corporate-governance)\n  * [ESG](/about-us/esg-environmental-social-and-governance \"ESG \\(Environmental, Social and Governance\\)\")\n\n\n\n[Close submenu (Executive Committee)](#mm-2)[Executive Committee](#mm-2)\n\n  * [Sijmen de Vries](/about-us/executive-committee/sijmen-de-vries)\n  * [Jeroen Wakkerman](/about-us/executive-committee/jeroen-wakkerman)\n  * [Anurag Relan](/about-us/executive-committee/anurag-relan)\n  * [Stephen Toor](/about-us/executive-committee/stephen-toor)\n  * [Mireille Sanders, MSc](/about-us/executive-committee/mireille-sanders)\n  * [Ruud van Outersterp](/about-us/executive-committee/ruud-van-outersterp)\n  * [Dr. Alexander Breidenbach](/about-us/executive-committee/alexander-breidenbach)\n\n\n\n[Close submenu (Board of Directors)](#mm-2)[Board of Directors](#mm-2)\n\n  * [Deborah Jorn, MBA](/about-us/board-directors/deborah-jorn)\n  * [Barbara Yanni](/about-us/board-directors/barbara-yanni)\n  * [Mark Pykett, VMD, PhD](/about-us/board-directors/mark-pykett)\n  * [Leonard Kruimer](/about-us/board-directors/leonard-kruimer)\n  * [Jabine van der Meijs](/about-us/board-directors/jabine-van-der-meijs)\n  * [Richard Peters, MD, PhD](/about-us/board-directors/dr-richard-peters)\n  * [Steven Baert](/about-us/board-directors/steven-baert)\n\n\n\n[Close submenu (Investors)](#mm-1)[Investors](#mm-1)\n\n  * [Upcoming events](/investors/upcoming-events)\n  * [Corporate Presentations](/investors/corporate-presentations)\n  * [Shareholder Meetings](/investors/shareholder-meetings)\n  * [Financial documents](/investors/financial-documents)\n  * [Analyst Coverage](/investors/analyst-coverage)\n  * [SEC filings](/investors/sec-filings)\n  * [FAQ](/investors/faq)\n\n\n\n[Close submenu (Contact)](#mm-1)[Contact](#mm-1)\n\n  * [Report an adverse event](/report-adverse-event)\n\n\n\n[ Skip to main content ](#main)\n\nSearch  Search \n\n## [ Pharming  ![Logo Pharming](/assets/images/logo_pharming.svg) ](https://www.pharming.com/) [ Search  ](#searchCollapse) [ Menu  ](#hamburgermenu)\n\nglobal \n\n  * [Home](/)\n  * [About Us](/about-us)\n    * [Executive Committee](/about-us/executive-committee)\n    * [Board of Directors](/about-us/board-directors)\n    * [Corporate Governance](/about-us/corporate-governance)\n    * [ESG](/about-us/esg-environmental-social-and-governance \"ESG \\(Environmental, Social and Governance\\)\")\n  * [Products](/products)\n  * [Pipeline](/pipeline)\n  * [Partnering](/partnering)\n  * [Investors](/investors)\n    * [Upcoming events](/investors/upcoming-events)\n    * [Corporate Presentations](/investors/corporate-presentations)\n    * [Shareholder Meetings](/investors/shareholder-meetings)\n    * [Financial documents](/investors/financial-documents)\n    * [Analyst Coverage](/investors/analyst-coverage)\n    * [SEC filings](/investors/sec-filings)\n    * [FAQ](/investors/faq)\n  * [News](/news)\n  * [Careers](/career-opportunities)\n  * [Contact](/contact)\n    * [Report an adverse event](/report-adverse-event)\n  * [ Search  ](#searchCollapse) [LanguageVerander taal](/nl/node/494)\n\n\n\n  1. [ Home ](/)\n  2. [ News ](/news)\n  3. Pharming Group reports third quarter 2024 financial results and provides business update \n\n\n\n#  Pharming Group reports third quarter 2024 financial results and provides business update \n\nFinancial updates  October 24, 2024 \n\n#  Pharming Group reports third quarter 2024 financial results and provides business update \n\nPharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2024. \n\n  * **Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growth**\n  * **RUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023**\n  * **Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023**\n  * **First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023**\n  * **On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)**\n  * **Third quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarter 2023**\n  * **Overall cash and marketable securities increased to US$173.3 million at the end of the third quarter 2024 from US$161.8 million at the end of the second quarter 2024**\n  * **Sijmen de Vries, our Executive Director/Chief Executive Officer, has informed the Board of Directors that he will not be available for reappointment at the next Annual General Meeting of Shareholders in May 2025**\n  * **Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (**[**view webcast**](https://edge.media-server.com/mmc/p/yotjk8ib)**or**[**register for the conference call**](https://register.vevent.com/register/BId118ac68d9124f67b1a83e3769559100)**)**\n\n\n\nRead full press release below\n\n[ Download full press release  EN  ](/sites/default/files/imce/Press%20releases/Pharming%20reports%203Q24%20financial%20results_EN_24OCT24.pdf)\n\n[ Download volledig persbericht  NL  ](/sites/default/files/imce/Press%20releases/Pharming%20reports%203Q24%20financial%20results_NL_24OCT24.pdf)\n\n[ Download presentation slides  EN  ](/sites/default/files/imce/Presentations/Pharming%203Q24%20presentation_24OCT24_website.pdf)\n\n[ Download transcript  EN  ](/sites/default/files/imce/Transcripts/3Q%202024%20Results%20Call%20Transcript_24OCT24.pdf)\n\n###  Subscribe to our press release distribution list \n\n####  Stay up to date on the latest news and information \n\nEnglish \n\nDutch \n\nSignup \n\nI understand and consent to the following [ Privacy Statement ](/privacy-statement)\n\nSignup  Signup \n\nCookies:  This website uses cookies [Check the cookies page](/cookies) for more information [ Accept ](javascript\\(\\);) [ Decline ](javascript\\(\\);)\n\n##  Taal aanpassen \n\nWilt u overschakelen naar een andere taal? Klik [ hier ](/nl) voor de Nederlandse website. \n\n[ Taal aanpassen ](/nl) [ Sluiten ](#)\n"
        }
      ]
    }
  ]
}